Effects of a cream containing 5% hyaluronic acid mixed with a bacterial-wall-derived glycoprotein, glycyrretinic acid, piroctone olamine and climbazole on signs, symptoms and skin bacterial microbiota in subjects with seborrheic dermatitis of the face

Mario Puviani, Elena Campione, Anna Maria Offidani, Roberta De Grandi, Luca Bianchi, Ivan Bobyr, Melania Giannoni, Anna Campanati, Marta Bottagisio, Alessandro Bidossi, Elena De Vecchi, Klaus Eisendle, Massimo Milani

Research output: Contribution to journalArticle

Abstract

Objective: A new cream formulation containing hyaluronic acid 5%, complexed with a mix of a bacterial-wall-derived glycoprotein and peptide glycan complex (EDS), has been recently developed. We evaluated in a prospective, assessor-blinded, 6-week study the efficacy and tolerability of EDS in the treatment of facial seborrheic dermatitis (SD) and the effects on skin microbiota. Subjects and methods: Seventy-five subjects (mean age 46; 60 men) with moderate severe SD of the face were enrolled. EDS cream was applied twice daily. The primary outcome was the evolution of the Investigator Global Assessment (IGA) score, evaluating erythema, scale/flaking, grade of seborrhea and itch. Superficial skin bacterial microbiome at baseline and after treatment was assessed, using the 16S rRNA gene methodology, in affected and non-affected face areas. Local tolerability was evaluated checking selfreported side effects at each visit. Results: Baseline IGA scores (mean±SD) was 10±3. The use of EDS reduced IGA score significantly by 70% at week 3 and by 88% at week 6. An increase in the abundance of Cutibacterium acnes genera associated with a significant drop of Staphylococcus genera presence was detected in affected areas. The ratio of relative abundance of genera Cutibacterium/Staphylococcus increased significantly after treatment in affected areas. The product was very well tolerated. Conclusion: Treatment with EDS applied twice daily for 6 consecutive weeks was associated with a reduction of the signs and symptoms of SD. Furthermore, after EDS cream treatment, a reequilibrating effect on facial skin microbiota was observed. The product was very well tolerated.

Original languageEnglish
Pages (from-to)285-293
Number of pages9
JournalClinical, Cosmetic and Investigational Dermatology
Volume12
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Seborrheic Dermatitis
Microbiota
Hyaluronic Acid
Signs and Symptoms
Glycoproteins
Skin
Acids
Research Personnel
Staphylococcus
Therapeutics
Acne Vulgaris
Erythema
rRNA Genes
Polysaccharides
piroctone olamine
climbazole
Peptides

Keywords

  • Assessor blinded trial
  • Hyaluronic acid
  • Seborrheic dermatitis
  • Skin microbiota

ASJC Scopus subject areas

  • Dermatology

Cite this

Effects of a cream containing 5% hyaluronic acid mixed with a bacterial-wall-derived glycoprotein, glycyrretinic acid, piroctone olamine and climbazole on signs, symptoms and skin bacterial microbiota in subjects with seborrheic dermatitis of the face. / Puviani, Mario; Campione, Elena; Offidani, Anna Maria; Grandi, Roberta De; Bianchi, Luca; Bobyr, Ivan; Giannoni, Melania; Campanati, Anna; Bottagisio, Marta; Bidossi, Alessandro; Vecchi, Elena De; Eisendle, Klaus; Milani, Massimo.

In: Clinical, Cosmetic and Investigational Dermatology, Vol. 12, 01.01.2019, p. 285-293.

Research output: Contribution to journalArticle

Puviani, Mario ; Campione, Elena ; Offidani, Anna Maria ; Grandi, Roberta De ; Bianchi, Luca ; Bobyr, Ivan ; Giannoni, Melania ; Campanati, Anna ; Bottagisio, Marta ; Bidossi, Alessandro ; Vecchi, Elena De ; Eisendle, Klaus ; Milani, Massimo. / Effects of a cream containing 5% hyaluronic acid mixed with a bacterial-wall-derived glycoprotein, glycyrretinic acid, piroctone olamine and climbazole on signs, symptoms and skin bacterial microbiota in subjects with seborrheic dermatitis of the face. In: Clinical, Cosmetic and Investigational Dermatology. 2019 ; Vol. 12. pp. 285-293.
@article{48f0f59b63284b2b8f41f57a858ebf03,
title = "Effects of a cream containing 5{\%} hyaluronic acid mixed with a bacterial-wall-derived glycoprotein, glycyrretinic acid, piroctone olamine and climbazole on signs, symptoms and skin bacterial microbiota in subjects with seborrheic dermatitis of the face",
abstract = "Objective: A new cream formulation containing hyaluronic acid 5{\%}, complexed with a mix of a bacterial-wall-derived glycoprotein and peptide glycan complex (EDS), has been recently developed. We evaluated in a prospective, assessor-blinded, 6-week study the efficacy and tolerability of EDS in the treatment of facial seborrheic dermatitis (SD) and the effects on skin microbiota. Subjects and methods: Seventy-five subjects (mean age 46; 60 men) with moderate severe SD of the face were enrolled. EDS cream was applied twice daily. The primary outcome was the evolution of the Investigator Global Assessment (IGA) score, evaluating erythema, scale/flaking, grade of seborrhea and itch. Superficial skin bacterial microbiome at baseline and after treatment was assessed, using the 16S rRNA gene methodology, in affected and non-affected face areas. Local tolerability was evaluated checking selfreported side effects at each visit. Results: Baseline IGA scores (mean±SD) was 10±3. The use of EDS reduced IGA score significantly by 70{\%} at week 3 and by 88{\%} at week 6. An increase in the abundance of Cutibacterium acnes genera associated with a significant drop of Staphylococcus genera presence was detected in affected areas. The ratio of relative abundance of genera Cutibacterium/Staphylococcus increased significantly after treatment in affected areas. The product was very well tolerated. Conclusion: Treatment with EDS applied twice daily for 6 consecutive weeks was associated with a reduction of the signs and symptoms of SD. Furthermore, after EDS cream treatment, a reequilibrating effect on facial skin microbiota was observed. The product was very well tolerated.",
keywords = "Assessor blinded trial, Hyaluronic acid, Seborrheic dermatitis, Skin microbiota",
author = "Mario Puviani and Elena Campione and Offidani, {Anna Maria} and Grandi, {Roberta De} and Luca Bianchi and Ivan Bobyr and Melania Giannoni and Anna Campanati and Marta Bottagisio and Alessandro Bidossi and Vecchi, {Elena De} and Klaus Eisendle and Massimo Milani",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/CCID.S205904",
language = "English",
volume = "12",
pages = "285--293",
journal = "Clinical, Cosmetic and Investigational Dermatology",
issn = "1178-7015",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Effects of a cream containing 5% hyaluronic acid mixed with a bacterial-wall-derived glycoprotein, glycyrretinic acid, piroctone olamine and climbazole on signs, symptoms and skin bacterial microbiota in subjects with seborrheic dermatitis of the face

AU - Puviani, Mario

AU - Campione, Elena

AU - Offidani, Anna Maria

AU - Grandi, Roberta De

AU - Bianchi, Luca

AU - Bobyr, Ivan

AU - Giannoni, Melania

AU - Campanati, Anna

AU - Bottagisio, Marta

AU - Bidossi, Alessandro

AU - Vecchi, Elena De

AU - Eisendle, Klaus

AU - Milani, Massimo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: A new cream formulation containing hyaluronic acid 5%, complexed with a mix of a bacterial-wall-derived glycoprotein and peptide glycan complex (EDS), has been recently developed. We evaluated in a prospective, assessor-blinded, 6-week study the efficacy and tolerability of EDS in the treatment of facial seborrheic dermatitis (SD) and the effects on skin microbiota. Subjects and methods: Seventy-five subjects (mean age 46; 60 men) with moderate severe SD of the face were enrolled. EDS cream was applied twice daily. The primary outcome was the evolution of the Investigator Global Assessment (IGA) score, evaluating erythema, scale/flaking, grade of seborrhea and itch. Superficial skin bacterial microbiome at baseline and after treatment was assessed, using the 16S rRNA gene methodology, in affected and non-affected face areas. Local tolerability was evaluated checking selfreported side effects at each visit. Results: Baseline IGA scores (mean±SD) was 10±3. The use of EDS reduced IGA score significantly by 70% at week 3 and by 88% at week 6. An increase in the abundance of Cutibacterium acnes genera associated with a significant drop of Staphylococcus genera presence was detected in affected areas. The ratio of relative abundance of genera Cutibacterium/Staphylococcus increased significantly after treatment in affected areas. The product was very well tolerated. Conclusion: Treatment with EDS applied twice daily for 6 consecutive weeks was associated with a reduction of the signs and symptoms of SD. Furthermore, after EDS cream treatment, a reequilibrating effect on facial skin microbiota was observed. The product was very well tolerated.

AB - Objective: A new cream formulation containing hyaluronic acid 5%, complexed with a mix of a bacterial-wall-derived glycoprotein and peptide glycan complex (EDS), has been recently developed. We evaluated in a prospective, assessor-blinded, 6-week study the efficacy and tolerability of EDS in the treatment of facial seborrheic dermatitis (SD) and the effects on skin microbiota. Subjects and methods: Seventy-five subjects (mean age 46; 60 men) with moderate severe SD of the face were enrolled. EDS cream was applied twice daily. The primary outcome was the evolution of the Investigator Global Assessment (IGA) score, evaluating erythema, scale/flaking, grade of seborrhea and itch. Superficial skin bacterial microbiome at baseline and after treatment was assessed, using the 16S rRNA gene methodology, in affected and non-affected face areas. Local tolerability was evaluated checking selfreported side effects at each visit. Results: Baseline IGA scores (mean±SD) was 10±3. The use of EDS reduced IGA score significantly by 70% at week 3 and by 88% at week 6. An increase in the abundance of Cutibacterium acnes genera associated with a significant drop of Staphylococcus genera presence was detected in affected areas. The ratio of relative abundance of genera Cutibacterium/Staphylococcus increased significantly after treatment in affected areas. The product was very well tolerated. Conclusion: Treatment with EDS applied twice daily for 6 consecutive weeks was associated with a reduction of the signs and symptoms of SD. Furthermore, after EDS cream treatment, a reequilibrating effect on facial skin microbiota was observed. The product was very well tolerated.

KW - Assessor blinded trial

KW - Hyaluronic acid

KW - Seborrheic dermatitis

KW - Skin microbiota

UR - http://www.scopus.com/inward/record.url?scp=85072814436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072814436&partnerID=8YFLogxK

U2 - 10.2147/CCID.S205904

DO - 10.2147/CCID.S205904

M3 - Article

AN - SCOPUS:85072814436

VL - 12

SP - 285

EP - 293

JO - Clinical, Cosmetic and Investigational Dermatology

JF - Clinical, Cosmetic and Investigational Dermatology

SN - 1178-7015

ER -